幼童应用生物可吸收支架行经皮冠状动脉介入治疗
本文报告一例3岁纯合子家族性高胆固醇血症患儿因不稳定多支冠状动脉病变接受生物可吸收支架经皮冠状动脉介入治疗,术后3个月无心血管症状并存活至肝移植,尸检显示支架通畅伴非阻塞性新生内膜增生。
要点
- 3岁纯合子家族性高胆固醇血症患儿因不稳定多支冠状动脉病变接受生物可吸收支架经皮冠状动脉介入治疗。
- 术后3个月无心血管症状并存活至肝移植,后死于非心脏并发症。
- 尸检组织学显示两枚生物可吸收支架均通畅伴非阻塞性新生内膜增生。
核心结论
- 据作者所知,这是首例儿童应用生物可吸收支架行经皮冠状动脉介入治疗的报告。
- 作者认为这代表了生物可吸收支架的一种应用,可能对儿童冠状动脉疾病的未来治疗具有潜在重要意义,并需要进一步研究。
研究设计与样本
- 本文为来自学术三级医疗机构的病例报告,对象为一名3岁纯合子家族性高胆固醇血症患儿,因不稳定冠状动脉疾病需血运重建。
- 本文同时简要回顾了相关文献。
主要发现
- 对右冠状动脉近段、左主干及左回旋支近段行血管内成像指导的经皮冠状动脉介入治疗并植入生物可吸收支架。
- 生物可吸收支架植入后,患者恢复,经皮冠状动脉介入治疗后3个月无心血管症状。
- 患者随后接受原位肝移植以根治纯合子家族性高胆固醇血症,但死于非心脏并发症。
- 尸检包括组织学评估显示两枚生物可吸收支架均通畅,伴非阻塞性新生内膜增生。
关键数值与推荐
- 主要结局为急性手术成功和存活至肝移植(经皮冠状动脉介入治疗后3个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although much less frequent than in adults, coronary artery disease requiring revascularization may develop in children because of homozygous familial hypercholesterolemia or other underlying conditions. Percutaneous coronary intervention (PCI) with a bioresorbable scaffold (BRS) may have advantages over metallic coronary stents in this population. OBJECTIVE: To present a case of the successful treatment of unstable, multivessel coronary artery disease in a child with PCI with BRS implantation. This case highlights the limitations of conventional metal stents and the potential benefits of using BRSs in children. DESIGN, SETTING, AND PARTICIPANTS: This is a case report from an academic tertiary care institution of a 3-year-old boy with homozygous familial hypercholesterolemia and unstable coronary artery disease requiring revascularization. We also briefly review the related literature. INTERVENTIONS/EXPOSURES: Intravascular imaging-guided PCI of the proximal right coronary artery and the left main and proximal left circumflex arteries was performed with BRSs. MAIN OUTCOMES AND MEASURES: The primary outcomes were acute procedural success and survival to liver transplant (3 months after PCI). RESULTS: Following BRS implantation, the patient recovered and remained free of cardiovascular symptoms 3 months after PCI. He subsequently underwent an orthotopic liver transplant for definitive treatment of homozygous familial hypercholesterolemia but died of noncardiac complications. A postmortem examination, including a histological assessment, revealed both BRSs to be patent with nonobstructive neointimal hyperplasia. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first report of PCI with BRSs in a child. This represents an application of a BRS with potentially important implications for the future treatment of coronary artery disease in children and warrants further study.
引用
- Nazif TM, Kalra S, Ali ZA, et al. Percutaneous Coronary Intervention With Bioresorbable Scaffolds in a Young Child. JAMA Cardiol. 2017. PMID: 28030655. doi:10.1001/jamacardio.2016.4954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。